User:Mr. Ibrahem/Selexipag
 | |
| Clinical data | |
|---|---|
| Trade names | Uptravi |
| Other names | ACT-293987, NS-304 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth, intravenous |
| Drug class | Prostacyclin receptor agonist[1] |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C26H32N4O4S |
| Molar mass | 496.63 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Selexipag, sold under the brand name Uptravi, is a medication used to treat pulmonary arterial hypertension (PAH).[2] Generally it is used in people in who an endothelin receptor antagonist and PDE5 inhibitor are not enough.[4] It is taken by mouth or injection into a vein.[2]
Common side effects include headache, diarrhea, muscle pain, flushing, and rash.[3] Other side effects can include pulmonary edema.[3] It should not be used in people with significant coronary artery disease or valvular heart disease.[1] It works by activating the prostacyclin receptor which causes the muscles in blood vessels to relax.[1]
Selexipag was approved for medical use in the United States in 2015 and Europe in 2016.[3][1] In the United States it costs about 20,100 USD a month as of 2021.[5] In the United Kingdom this amount costs the NHS about £3,000.[4]
References[edit]
- ^ a b c d "Uptravi". Archived from the original on 12 May 2021. Retrieved 11 October 2021.
- ^ a b c d e "Uptravi- selexipag tablet, coated Uptravi Titration Pack- selexipag kit". DailyMed. Archived from the original on 30 July 2021. Retrieved 30 July 2021.
- ^ a b c d "Selexipag Monograph for Professionals". Drugs.com. Retrieved 11 October 2021.
- ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 194. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Uptravi Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 3 August 2020. Retrieved 11 October 2021.